GlassScriptPhysician profile
Wesley Chad Turner
NPI 1013326834
$695.12
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $15.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $141.95 | 2019 | |
| Novo Nordisk INC | $112.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.58 | 2019 | |
| Merck Sharp & Dohme LLC | $49.91 | 2019 | |
| Astellas Pharma US INC | $40.73 | 2019 | |
| Lilly USA, LLC | $37.96 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.28 | 2019 | |
| Pfizer INC. | $28.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.55 | 2019 | |
| Mannkind Corporation | $22.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.77 | 2019 | |
| Medtronic USA, INC. | $15.41 | 2020 | |
| Neurocrine Biosciences, INC. | $13.08 | 2019 | |
| Allergan, INC. | $11.73 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.